Posted On: 09/30/2015 1:22:20 PM
Post# of 72446
This shows you how underpriced CTIX is. CTIX market cap, 170 million. AVXL market cap, 167 million.
CTIX has 3 drugs in human trials for 4 indications, with no safety concerns and anecdotal positive evidence of efficacy (even though proof of efficacy is not the goal in phase 1 trials -- safety is the goall).
AVXL is early in phase 1 human trials for 1 drug.
CTIX has 3 drugs in human trials for 4 indications, with no safety concerns and anecdotal positive evidence of efficacy (even though proof of efficacy is not the goal in phase 1 trials -- safety is the goall).
AVXL is early in phase 1 human trials for 1 drug.
(0)
(0)
